

VPA10980/027/001

Recudon 2.5 mg/ml + 0.125 mg/ml solution for injection for horses and dogs

Variation	Summary	Date
Vet - B21	VNRA - Vet - B21 - - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product	31/03/26
Vet - B22	VNRA - Vet - B22 - - Vet - B22 - Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product	31/03/26
Vet - F.II.f.1 a) 1.	VRA-R - Vet - F.II.f.1 a) 1. - - Vet - F.II.f.1 a) 1. - Change in the shelf-life or storage conditions of the finished product - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	11/11/25
Vet - F.II.b.1 d)	VRA-R - Vet - F.II.b.1 d) - - Vet - F.II.b.1 d) - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterinary medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products	29/08/25
Vet - B45	VNRA - Vet - B45 - Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile active substance, starting material, reagent or intermediate, excipient - B45 Changes to the quality part of the dossier: Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	15/04/25
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	11/03/25
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	11/03/25